Clinical Trial Update: Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3) [Phase 2]

View source ↗

Summary

A Phase 2 study (SILEN-C3) evaluated short-term treatment with BI 201335 in combination with peginterferon-alfa-2a and ribavirin in genotype-1 hepatitis C treat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 201335
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2015-09-07